New research pinpoints key pathways in prostate cancer’s vulnerability to ferroptosis

Review examines the role of ferroptosis, an iron-dependent form of cell death, in prostate cancer, exploring its underlying molecular mechanisms and potential for targeted therapeutic strategies.

Dana-Farber deal highlights a surprising trend: New cancer centers are in vogue

Boston isn’t the only city slated for a new cancer center. Far from it. There’s little appetite to build general acute-care hospitals, especially as their

September 15, 2023

Philogen, Sun Pharma seek EMA approval for melanoma therapy

Intended to be administered intralesionally for four weeks, Nidlegy aims to enhance the immune response against neoplastic lesions. Credit: New Africa / Shutterstock. Philogen and

June 4, 2024

Cerevance raises $47m to fund Phase III trial for lead Parkinson’s therapy

Share this article Cerevance’s CVN424 is a non-dopamine G protein-coupled receptor 6 (GPR6) inhibitor. Image Credit: Pla2na / Shutterstrock. US-based Cerevance has secured $47m in

April 26, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.